Literature DB >> 25381133

A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia.

Anna Kalff1, Tiffany Khong1, Meaghan Wall2, Malgorzata Gorniak3, Sridurga Mithraprabhu1, Lynda J Campbell2, Andrew Spencer4.   

Abstract

Entities:  

Keywords:  IGH/MYC; leukemia; primary plasma cell

Mesh：

Substances：

Year:  2014        PMID： 25381133      PMCID： PMC4803129          DOI： 10.3324/haematol.2014.111385

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience.

Authors:  H Avet-Loiseau; M Roussel; L Campion; X Leleu; G Marit; H Jardel; M Dib; O Decaux; T Lamy; M Tiab; P Cony-Makhoul; A Banos; G Lepeu; F Lifermann; M Macro; B Kolb; C Hulin; D Caillot; C Traulle; C Mathiot; B Royer
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

3.  Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.

Authors:  Misuk Ji; Seongsoo Jang; Je-Hwan Lee; Eul-Ju Seo
Journal:  Ann Hematol       Date:  2013-01-10       Impact factor: 3.673

Review 4.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

5.  Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis.

Authors:  Anuradha Kanungo; L Jeffrey Medeiros; Lynne V Abruzzo; Pei Lin
Journal:  Mod Pathol       Date:  2006-01       Impact factor: 7.842

6.  CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations.

Authors:  S Kumar; S V Rajkumar; T Kimlinger; P R Greipp; T E Witzig
Journal:  Leukemia       Date:  2005-08       Impact factor: 11.528

Review 7.  Double-hit B-cell lymphomas.

Authors:  Sietse M Aukema; Reiner Siebert; Ed Schuuring; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Evert-Jan Boerma; Philip M Kluin
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

8.  Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

Authors:  Kewal Asosingh; Hendrik De Raeve; Eline Menu; Ivan Van Riet; Eric Van Marck; Benjamin Van Camp; Karin Vanderkerken
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113

Review 9.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

10.  Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.

Authors:  H A F Stessman; A Mansoor; F Zhan; S Janz; M A Linden; L B Baughn; B Van Ness
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528
View more
  2 in total

1.  BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.

Authors:  Simon J Hogg; Stephin J Vervoort; Sumit Deswal; Christopher J Ott; Jason Li; Leonie A Cluse; Paul A Beavis; Phillip K Darcy; Benjamin P Martin; Andrew Spencer; Anna K Traunbauer; Irina Sadovnik; Karin Bauer; Peter Valent; James E Bradner; Johannes Zuber; Jake Shortt; Ricky W Johnstone
Journal:  Cell Rep       Date:  2017-02-28       Impact factor: 9.423

2.  Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma.

Authors:  Sridurga Mithraprabhu; Shreerang Sirdesai; Maoshan Chen; Tiffany Khong; Andrew Spencer
Journal:  Int J Mol Sci       Date:  2018-06-24       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.